View DividendLevel Bio 경영진경영진 기준 점검 1/4현재 CEO에 대한 정보가 충분하지 않습니다.핵심 정보Joakim Granemo최고경영자n/a총 보수CEO 급여 비율n/aCEO 재임 기간2.8yrsCEO 지분 보유율n/a경영진 평균 재임 기간데이터 없음이사회 평균 재임 기간5yrs최근 경영진 업데이트Board Change • May 20No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 6 experienced directors. 2 highly experienced directors. No independent directors (7 non-independent directors). Director Mikael Kubista was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공시 • Mar 20AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Apr 18, 2024AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Apr 18, 2024.공시 • May 31AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Jun 29, 2023AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Jun 29, 2023.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Joakim Grånemo was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Neven Zoric was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.모든 업데이트 보기Recent updatesBoard Change • May 20No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 6 experienced directors. 2 highly experienced directors. No independent directors (7 non-independent directors). Director Mikael Kubista was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공시 • Apr 02Devyser AB completed the acquisition of CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO).Devyser AB agreed to acquire CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) for SEK 12.2 million on February 11, 2026. The consideration consists of common equity of Devyser AB having a value of SEK 12.2 million to be issued for common equity of CyberGene AB. As part of consideration, SEK 12.2 million is paid towards common equity of CyberGene AB. The acquisition is fully financed through a directed issue of new shares in Devyser to the seller, to be paid by way of set-off against the seller’s claim on payment of the purchase price. Based on the authorization granted by the Annual General Meeting on 14 May 2025, the Board of Directors intends, subject to receipt of the necessary clearance from the Inspectorate of Strategic Products, to resolve upon an issue of new shares in Devyser. Level Bio AB (publ), as the seller of Cybergene, will be entitled to subscribe for the new shares. The transaction is subject to approval by regulatory board / committee. The expected completion of the transaction is April 1, 2026. The acquisition strengthens Devyser’s customer offering within the aneuploidy segment and is expected to have a positive impact on Devyser’s gross profit and gross margin. Devyser AB completed the acquisition of CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) on April 1, 2026. The acquisition was conditional upon the receipt of all necessary clearances, approvals, decisions and other actions from the Inspectorate of Strategic Products under the Swedish Screening of Foreign Direct Investments Act. This closing condition has been fulfilled on April 1, 2026. The acquisition is consolidated from and including April 1, 2026 and is expected to have a positive impact on Devyser’s gross profit as well as EBIT.공시 • Feb 12Devyser AB agreed to acquire CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) for SEK 12.2 million.Devyser AB agreed to acquire CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) for SEK 12.2 million on February 11, 2026. The consideration consists of common equity of Devyser AB having a value of SEK 12.2 million to be issued for common equity of CyberGene AB. As part of consideration, SEK 12.2 million is paid towards common equity of CyberGene AB. The transaction is subject to approval by regulatory board / committee. The expected completion of the transaction is April 1, 2026. The acquisition strengthens Devyser’s customer offering within the aneuploidy segment and is expected to have a positive impact on Devyser’s gross profit and gross margin. The acquisition is fully financed through a directed issue of new shares in Devyser to the seller, to be paid by way of set-off against the seller’s claim on payment of the purchase price. Based on the authorization granted by the Annual General Meeting on 14 May 2025, the Board of Directors intends, subject to receipt of the necessary clearance from the Inspectorate of Strategic Products, to resolve upon an issue of new shares in Devyser. Level Bio AB (publ), as the seller of Cybergene, will be entitled to subscribe for the new shares.Reported Earnings • Apr 26First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: kr5.67m (down 33% from 1Q 2023). Net loss: kr2.46m (loss widened 343% from 1Q 2023).공시 • Mar 27AlphaHelix Molecular Diagnostics AB (publ) to Report Q1, 2024 Results on Apr 25, 2024AlphaHelix Molecular Diagnostics AB (publ) announced that they will report Q1, 2024 results on Apr 25, 2024공시 • Mar 20AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Apr 18, 2024AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Apr 18, 2024.Reported Earnings • Feb 25Full year 2023 earnings released: kr0.15 loss per share (vs kr0.035 loss in FY 2022)Full year 2023 results: kr0.15 loss per share (further deteriorated from kr0.035 loss in FY 2022). Revenue: kr26.6m (down 23% from FY 2022). Net loss: kr9.48m (loss widened 326% from FY 2022).공시 • Jan 24AlphaHelix Molecular Diagnostics AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2024AlphaHelix Molecular Diagnostics AB (publ) announced that they will report fiscal year 2023 results on Feb 22, 2024Reported Earnings • Oct 29Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: kr6.54m (up 19% from 3Q 2022). Net loss: kr2.30m (loss widened 93% from 3Q 2022).공시 • Sep 27AlphaHelix Molecular Diagnostics AB (publ) to Report Q3, 2023 Results on Oct 26, 2023AlphaHelix Molecular Diagnostics AB (publ) announced that they will report Q3, 2023 results on Oct 26, 2023Reported Earnings • Aug 28Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr5.39m (down 6.3% from 2Q 2022). Net loss: kr2.36m (loss narrowed 2.4% from 2Q 2022).공시 • Jul 26AlphaHelix Molecular Diagnostics AB (publ) to Report Q2, 2023 Results on Aug 24, 2023AlphaHelix Molecular Diagnostics AB (publ) announced that they will report Q2, 2023 results on Aug 24, 2023공시 • May 31AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Jun 29, 2023AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Jun 29, 2023.Reported Earnings • Apr 20First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr8.48m (down 35% from 1Q 2022). Net loss: kr554.0k (down 139% from profit in 1Q 2022).Buying Opportunity • Apr 03Now 34% undervalued after recent price dropOver the last 90 days, the stock is down 31%. The fair value is estimated to be €0.049, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company became loss making.Buying Opportunity • Mar 07Now 37% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be €0.058, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company became loss making.Reported Earnings • Feb 24Full year 2022 earnings released: kr0.035 loss per share (vs kr0.087 profit in FY 2021)Full year 2022 results: kr0.035 loss per share (down from kr0.087 profit in FY 2021). Revenue: kr34.7m (down 21% from FY 2021). Net loss: kr2.22m (down 143% from profit in FY 2021).공시 • Jan 18AlphaHelix Molecular Diagnostics AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023AlphaHelix Molecular Diagnostics AB (publ) announced that they will report fiscal year 2022 results on Feb 16, 2023Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Joakim Grånemo was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 30Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr5.63m (down 16% from 3Q 2021). Net loss: kr1.19m (loss widened kr1.09m from 3Q 2021).Reported Earnings • Apr 27First quarter 2022 earnings released: EPS: kr0.022 (vs kr0.031 in 1Q 2021)First quarter 2022 results: EPS: kr0.022 (down from kr0.031 in 1Q 2021). Revenue: kr13.1m (up 39% from 1Q 2021). Net income: kr1.42m (down 12% from 1Q 2021). Profit margin: 11% (down from 17% in 1Q 2021). The decrease in margin was driven by higher expenses.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Neven Zoric was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 22First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: kr13.2m (up 40% from 1Q 2021). Net income: kr1.42m (down 12% from 1Q 2021). Profit margin: 11% (down from 17% in 1Q 2021). The decrease in margin was driven by higher expenses.Reported Earnings • Feb 18Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: kr0.081 (up from kr0.029 in FY 2020). Revenue: kr44.7m (up 90% from FY 2020). Net income: kr5.16m (up 241% from FY 2020). Profit margin: 12% (up from 6.4% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates.Reported Earnings • Nov 01Third quarter 2021 earnings releasedThe company reported a mediocre third quarter result with weaker earnings and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: kr6.96m (up 42% from 3Q 2020). Net loss: kr107.0k (down 168% from profit in 3Q 2020).Reported Earnings • Aug 18Second quarter 2021 earnings released: EPS kr0.056 (vs kr0.014 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: kr15.8m (up 153% from 2Q 2020). Net income: kr3.54m (up 363% from 2Q 2020). Profit margin: 22% (up from 12% in 2Q 2020). The increase in margin was driven by higher revenue.CEO 보수 분석Joakim Granemo의 보수는 Level Bio의 수익에 비해 어떻게 변했나요?날짜총 보수급여회사 수익Mar 31 2026n/an/a-SEK 3mDec 31 2025n/an/a-SEK 4mSep 30 2025n/an/a-SEK 4mJun 30 2025n/an/a-SEK 5mMar 31 2025n/an/a-SEK 6mDec 31 2024n/an/a-SEK 8mSep 30 2024n/an/a-SEK 11mJun 30 2024n/an/a-SEK 12mMar 31 2024n/an/a-SEK 11mDec 31 2023SEK 1mSEK 981k-SEK 9mSep 30 2023n/an/a-SEK 5mJun 30 2023n/an/a-SEK 4mMar 31 2023n/an/a-SEK 4mDec 31 2022SEK 866kSEK 768k-SEK 2m보상 대 시장: German 시장에서 비슷한 규모 기업과 비교해 Joakim의 총 보수가 적절한지 판단하기에 데이터가 부족합니다.보상과 수익: Joakim의 보상은 회사가 적자임에도 증가했습니다.CEOJoakim Granemo (39 yo)2.8yrs재임 기간Mr. Joakim Granemo is Chief Executive Officer of Level Bio AB (publ) from August 2023 and its Director from October 2022.이사회 구성원이름직위재임 기간보수지분Joakim GranemoCEO & Director3.6yrs데이터 없음데이터 없음Ulrica KarlssonCFO & Directorno dataSEK 945.00k데이터 없음Helene OlssonDirector of Cybergene ABno dataSEK 605.00k데이터 없음Mikael KubistaDirector2.3yrsSEK 25.00k데이터 없음Mikael HavsjoDirector15.2yrsSEK 50.00k데이터 없음Artur AiraChairman8.3yrsSEK 100.00k데이터 없음Tobias SchönDirector3.3yrsSEK 50.00k6.85% € 132.9kNeven ZoricDirector6.3yrsSEK 50.00k데이터 없음Claes GustafssonDirector of Techtum Lab ABno dataSEK 976.00k데이터 없음더 보기5.0yrs평균 재임 기간56yo평균 나이경험이 풍부한 이사회: 4MB의 이사회는 경험이 있음으로 간주됩니다(평균 재임 5 년).View Ownership기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 04:24종가2026/05/22 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Level Bio AB (publ)는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Board Change • May 20No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 6 experienced directors. 2 highly experienced directors. No independent directors (7 non-independent directors). Director Mikael Kubista was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공시 • Mar 20AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Apr 18, 2024AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Apr 18, 2024.
공시 • May 31AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Jun 29, 2023AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Jun 29, 2023.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Joakim Grånemo was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Neven Zoric was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • May 20No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 6 experienced directors. 2 highly experienced directors. No independent directors (7 non-independent directors). Director Mikael Kubista was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공시 • Apr 02Devyser AB completed the acquisition of CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO).Devyser AB agreed to acquire CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) for SEK 12.2 million on February 11, 2026. The consideration consists of common equity of Devyser AB having a value of SEK 12.2 million to be issued for common equity of CyberGene AB. As part of consideration, SEK 12.2 million is paid towards common equity of CyberGene AB. The acquisition is fully financed through a directed issue of new shares in Devyser to the seller, to be paid by way of set-off against the seller’s claim on payment of the purchase price. Based on the authorization granted by the Annual General Meeting on 14 May 2025, the Board of Directors intends, subject to receipt of the necessary clearance from the Inspectorate of Strategic Products, to resolve upon an issue of new shares in Devyser. Level Bio AB (publ), as the seller of Cybergene, will be entitled to subscribe for the new shares. The transaction is subject to approval by regulatory board / committee. The expected completion of the transaction is April 1, 2026. The acquisition strengthens Devyser’s customer offering within the aneuploidy segment and is expected to have a positive impact on Devyser’s gross profit and gross margin. Devyser AB completed the acquisition of CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) on April 1, 2026. The acquisition was conditional upon the receipt of all necessary clearances, approvals, decisions and other actions from the Inspectorate of Strategic Products under the Swedish Screening of Foreign Direct Investments Act. This closing condition has been fulfilled on April 1, 2026. The acquisition is consolidated from and including April 1, 2026 and is expected to have a positive impact on Devyser’s gross profit as well as EBIT.
공시 • Feb 12Devyser AB agreed to acquire CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) for SEK 12.2 million.Devyser AB agreed to acquire CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) for SEK 12.2 million on February 11, 2026. The consideration consists of common equity of Devyser AB having a value of SEK 12.2 million to be issued for common equity of CyberGene AB. As part of consideration, SEK 12.2 million is paid towards common equity of CyberGene AB. The transaction is subject to approval by regulatory board / committee. The expected completion of the transaction is April 1, 2026. The acquisition strengthens Devyser’s customer offering within the aneuploidy segment and is expected to have a positive impact on Devyser’s gross profit and gross margin. The acquisition is fully financed through a directed issue of new shares in Devyser to the seller, to be paid by way of set-off against the seller’s claim on payment of the purchase price. Based on the authorization granted by the Annual General Meeting on 14 May 2025, the Board of Directors intends, subject to receipt of the necessary clearance from the Inspectorate of Strategic Products, to resolve upon an issue of new shares in Devyser. Level Bio AB (publ), as the seller of Cybergene, will be entitled to subscribe for the new shares.
Reported Earnings • Apr 26First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: kr5.67m (down 33% from 1Q 2023). Net loss: kr2.46m (loss widened 343% from 1Q 2023).
공시 • Mar 27AlphaHelix Molecular Diagnostics AB (publ) to Report Q1, 2024 Results on Apr 25, 2024AlphaHelix Molecular Diagnostics AB (publ) announced that they will report Q1, 2024 results on Apr 25, 2024
공시 • Mar 20AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Apr 18, 2024AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Apr 18, 2024.
Reported Earnings • Feb 25Full year 2023 earnings released: kr0.15 loss per share (vs kr0.035 loss in FY 2022)Full year 2023 results: kr0.15 loss per share (further deteriorated from kr0.035 loss in FY 2022). Revenue: kr26.6m (down 23% from FY 2022). Net loss: kr9.48m (loss widened 326% from FY 2022).
공시 • Jan 24AlphaHelix Molecular Diagnostics AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2024AlphaHelix Molecular Diagnostics AB (publ) announced that they will report fiscal year 2023 results on Feb 22, 2024
Reported Earnings • Oct 29Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: kr6.54m (up 19% from 3Q 2022). Net loss: kr2.30m (loss widened 93% from 3Q 2022).
공시 • Sep 27AlphaHelix Molecular Diagnostics AB (publ) to Report Q3, 2023 Results on Oct 26, 2023AlphaHelix Molecular Diagnostics AB (publ) announced that they will report Q3, 2023 results on Oct 26, 2023
Reported Earnings • Aug 28Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr5.39m (down 6.3% from 2Q 2022). Net loss: kr2.36m (loss narrowed 2.4% from 2Q 2022).
공시 • Jul 26AlphaHelix Molecular Diagnostics AB (publ) to Report Q2, 2023 Results on Aug 24, 2023AlphaHelix Molecular Diagnostics AB (publ) announced that they will report Q2, 2023 results on Aug 24, 2023
공시 • May 31AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Jun 29, 2023AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Jun 29, 2023.
Reported Earnings • Apr 20First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr8.48m (down 35% from 1Q 2022). Net loss: kr554.0k (down 139% from profit in 1Q 2022).
Buying Opportunity • Apr 03Now 34% undervalued after recent price dropOver the last 90 days, the stock is down 31%. The fair value is estimated to be €0.049, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company became loss making.
Buying Opportunity • Mar 07Now 37% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be €0.058, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company became loss making.
Reported Earnings • Feb 24Full year 2022 earnings released: kr0.035 loss per share (vs kr0.087 profit in FY 2021)Full year 2022 results: kr0.035 loss per share (down from kr0.087 profit in FY 2021). Revenue: kr34.7m (down 21% from FY 2021). Net loss: kr2.22m (down 143% from profit in FY 2021).
공시 • Jan 18AlphaHelix Molecular Diagnostics AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023AlphaHelix Molecular Diagnostics AB (publ) announced that they will report fiscal year 2022 results on Feb 16, 2023
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Joakim Grånemo was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 30Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr5.63m (down 16% from 3Q 2021). Net loss: kr1.19m (loss widened kr1.09m from 3Q 2021).
Reported Earnings • Apr 27First quarter 2022 earnings released: EPS: kr0.022 (vs kr0.031 in 1Q 2021)First quarter 2022 results: EPS: kr0.022 (down from kr0.031 in 1Q 2021). Revenue: kr13.1m (up 39% from 1Q 2021). Net income: kr1.42m (down 12% from 1Q 2021). Profit margin: 11% (down from 17% in 1Q 2021). The decrease in margin was driven by higher expenses.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Neven Zoric was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 22First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: kr13.2m (up 40% from 1Q 2021). Net income: kr1.42m (down 12% from 1Q 2021). Profit margin: 11% (down from 17% in 1Q 2021). The decrease in margin was driven by higher expenses.
Reported Earnings • Feb 18Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: kr0.081 (up from kr0.029 in FY 2020). Revenue: kr44.7m (up 90% from FY 2020). Net income: kr5.16m (up 241% from FY 2020). Profit margin: 12% (up from 6.4% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates.
Reported Earnings • Nov 01Third quarter 2021 earnings releasedThe company reported a mediocre third quarter result with weaker earnings and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: kr6.96m (up 42% from 3Q 2020). Net loss: kr107.0k (down 168% from profit in 3Q 2020).
Reported Earnings • Aug 18Second quarter 2021 earnings released: EPS kr0.056 (vs kr0.014 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: kr15.8m (up 153% from 2Q 2020). Net income: kr3.54m (up 363% from 2Q 2020). Profit margin: 22% (up from 12% in 2Q 2020). The increase in margin was driven by higher revenue.